BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

Executive Summary

• BioVaxys Technology Corp. and Adiverna LLC have entered into a research agreement to co‑develop mRNA‑based vaccines for rabies, leptospirosis, and feline infectious peritonitis in companion animals (dogs and cats).
• The collaboration will combine BioVaxys’ DPX™ immune‑educating platform with Adiverna’s AI‑designed proprietary mRNA sequences, aiming to create the first commercially viable mRNA veterinary vaccines.
• Both parties highlight significant market opportunities: global rabies veterinary vaccine market projected at US$1.1 bn by 2030 and broader companion‑animal vaccine markets valued at several billions of dollars.

Key Details

• Partnership Scope: Development of DPX‑formulated mRNA vaccines targeting (i) Rabies, (ii) Leptospirosis, and (iii) Feline Infectious Peritonitis (FIV and related viruses).
• Technology Integration:
• BioVaxys provides the DPX™ non‑systemic depot delivery platform that forces active uptake of antigens into lymph nodes, offering dose‑sparing, enhanced stability, and prolonged T‑cell response.
• Adiverna supplies AI‑generated mRNA sequences encoding broadly cross‑neutralizing protective antigens for each target disease.
• Strategic Rationale: No mRNA vaccines are currently approved for companion animals; the partnership seeks to overcome limitations of lipid‑nanoparticle (LNP) formulations (e.g., systemic inflammation, nuclease degradation).
• Market Context:
• Rabies veterinary vaccine market: US$785 M in 2024 → ~US$1.1 B by 2030 (5.8% CAGR).
• Dog leptospirosis vaccine segment part of a $2.10 B dog‑vaccine market (2025).
• FIV/feline vaccine sector projected to reach US$3.28 B by 2034 (from US$1.77 B in 2025).
• Potential Advantages of DPX‑mRNA Vaccines:
• Longer‑lasting immunity with fewer doses versus traditional 1‑year or 3‑year animal vaccines.
• Absence of viral material, reduced impurities, improved safety profile.
• Micro‑dosing capability and superior shelf‑life stability.
• Leadership Comments:
• Kenneth Kovan (President & COO, BioVaxys) emphasized DPX’s ability to avoid LNP drawbacks and improve mRNA stability and immune targeting.
• Both CEOs expressed excitement about creating the world’s first mRNA veterinary vaccine and noted possible downstream applications of DPX‑mRNA in human therapeutics.
• Forward‑Looking Statements: The release contains typical forward‑looking language regarding development timelines, regulatory approvals, funding needs, and commercial potential.

Notable Quotes

“We are very excited to be working with Adiverna to develop what could be the world’s first mRNA veterinary vaccine… With demonstrated in vivo proof of concept of DPX mRNA formulations, this ‘proof of product’ will further our partnering discussions utilizing DPX mRNA formulations in human therapeutic applications.” – Kenneth Kovan, President & COO, BioVaxys

Materiality Assessment: Material – Positive (the agreement introduces a potentially transformative product line and opens sizable market opportunities for both companies).